JAPAN TOBACCO INC.
2914・Prime Market・Foods
Business
Japan Tobacco Inc. (JT) is a global enterprise comprising 225 consolidated subsidiaries and 20 equity-method affiliates. Its core Tobacco Business operates in more than 130 countries and regions, centered on JTI (JT International S.A.), and boasts a scale ranking within the top 3 in the industry (excluding China National Tobacco Corporation), owning 2 of the world's top 5 market-share brands (Winston and Camel). The Processed Foods Business is centered on Table Mark Co., Ltd., offering frozen udon, Packaged Rice (Domestic Koshihikari, etc.), and other products. In December 2025, the company transferred its Pharmaceuticals business to Shionogi & Co., Ltd., shifting to a structure that concentrates management resources on the two businesses of Tobacco and Processed Foods. Of revenue of ¥3,467,675 million (FY2025 (ending December 2025)), the Tobacco Business accounts for an overwhelming share.
Business Model
In the tobacco business, the company sells products in more than 130 countries and regions, centered on four Global Flagship Brands (GFBs): Winston, Camel, Mevius, and LD. Even amid tax increases, it implements price pass-through, establishing a profit model that offsets volume declines through unit price increases and mix improvement. RRPs (Reduced-Risk Products such as heated tobacco products) are developed under the Ploom brand, nurturing a next-generation revenue source. The processed food business contributes to the domestic market with value-added products leveraging proprietary manufacturing technology. The company has adopted a shareholder return policy targeting a payout ratio of 75%, returning its stable cash-generating capacity to shareholders.
Company Strengths
The company owns two of the world's top five brands by Combustibles sales volume share (Winston and Camel). In FY2025 (ending December 2025), GFB sales volume increased 2.8% year on year, with market share growth in approximately 50 markets including Italy, the UK, the US, and Turkey. Its sales network spanning over 130 countries and regions is a source of pricing power.
In FY2025 (ending December 2025), revenue from own tobacco products reached ¥3,184,400 million (up 14.6% year on year). Positive price/mix effects were realized across all clusters (Asia, Western Europe, and EMA), demonstrating a revenue structure that offsets volume-based market contraction through price and mix improvements. Adjusted operating profit reached ¥952,161 million (up 20.3% year on year).
RRP sales volume increased 28.0% year on year in FY2025 (ending December 2025) to 14.0 billion units, with Ploom sales volume growing substantially by 38.6% year on year. Revenue from RRP-related products increased 23.9% year on year to ¥122,500 million. Growth is being led by the Japanese market, and the company is advancing the establishment of the Ploom brand globally through priority investment in heated tobacco products.
ENVALITH's Perspective
Performance Trend
Revenue increased for five consecutive periods, from ¥2,324,838 million in FY2021 to ¥3,467,675 million in FY2025. Operating profit declined to ¥323,461 million in FY2024 due to one-off factors (litigation-related, etc.), but recovered sharply to ¥867,038 million in FY2025. In Q1 FY2026 (ending December 2026), revenue accelerated to ¥923,963 million (+15.2% YoY) and operating profit to ¥304,554 million (+24.7% YoY). As an external factor, yen depreciation against local currencies contributed to the boost in revenue, while price revisions and mix improvement across all clusters drove margin improvement. Full-year guidance calls for revenue of ¥3,697,000 million (+6.6% YoY) and operating profit of ¥921,000 million (+6.2% YoY), with Q1 progress rates of 25.0% for revenue and 33.1% for operating profit, indicating a favorable pace.
Growth Strategy
Pursuing sustainable profit growth through the twin pillars of maximizing Combustibles profitability and the global expansion of Ploom (RRP)
Driving price revisions and mix shift toward premium brands across all clusters to achieve revenue growth that more than offsets volume declines. In Q1 FY2026 (ending December 2026), revenue from own tobacco products reached ¥848,519 million (up 16.2% year on year), demonstrating strong growth.
Continuing to expand sales volume of RRP, centered on the heated tobacco brand Ploom. Building on its high share in the Japanese market, the company is accelerating expansion into overseas markets, pursuing a strategy of capturing demand shifting from Combustibles to RRP through its own brands.
Targeting average annual high single digit growth in adjusted operating profit on a constant currency basis over the three years from FY2026 (ending December 2026) to FY2028 (ending December 2028). In Q1 FY2026 (ending December 2026), adjusted operating profit on a constant currency basis reached ¥309,622 million (up 20.5% year on year), significantly outpacing the target growth rate. The full-year forecast stands at ¥964,000 million (up 8.9% year on year).
Having completed the transfer of the Pharmaceuticals business to Shionogi & Co., Ltd. and the sale of Torii Pharmaceutical Co., Ltd. shares, the company is concentrating management resources on its two segments: Tobacco and Processed Foods. The annual dividend forecast for FY2026 (ending December 2026) is ¥242 per share (an increase of ¥8 from ¥234 in the previous fiscal year), with a dividend payout ratio of 75.2%, maintaining a policy of high-level shareholder returns.
Last updated: July 17, 2026